Back to results
US 2023/0406838 A1Published application
Mutant selective egfr inhibitors and methods of use thereof
AssigneeDana-Farber Cancer Institute, Inc.
InventorsDavid Heppner, Michael Eck, Stefan Laufer, Florian Wittlinger, Marcel Guenther
Life of this patent
Estimating the term…
Abstract
The disclosure relates to compounds that act as inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.
Claims25
A compound of Formula I:
- or a pharmaceutically acceptable salt thereof;
- wherein:
- Z is C or S═O;
- Y is selected from the group consisting of NH, C1-C6 alkyl, C6-C10 aryl, 5-10 membered heteroaryl, C3-C10 cycloalkyl, and 3-10 membered heterocycloalkyl;
- alternatively, Z═O and Y are absent;
- A is 5-10 membered heteroaryl containing at least one nitrogen atom;
- alternatively, A and NHR2 are absent;
- B is selected from the group consisting of C6-C10 aryl, 5-10 membered heteroaryl, C3-C10 cycloalkyl, 3-10 membered heterocycloalkyl, and 5-10 membered bicyclic ring;
- R1 is C1-C6 alkyl;
- R2 is H, CO(C1-C6 alkyl), or C6-C10 aryl, wherein aryl is optionally substituted one or two times with R5;
- R3 is selected from the group consisting of H, halo, CN, OH, NH2, and CF3;
- each R4 is independently selected from the group consisting of H, OH, halo, C1-C6alkyl, C1-C6alkoxy, C6-C10 aryl, 5-10 membered heteroaryl, CH2-(5-10 membered bicyclic ring), and CH2NHC(O)(C6-C10 aryl), wherein aryl is optionally independently substituted one, two, or three times with halo, CO2H, or C1-C6 haloalkyl;
- each R5 is independently selected from the group consisting of halo, OH, C1-C6 alkoxy, and NHC(O)C2-C6 alkenyl and
- R6 is H or C1-C6 alkyl.
11 more elements
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.